Handel Entero Therapeutics Inc - ENTO CFD

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, specializes in the development of targeted, non-systemic therapies for gastrointestinal diseases. The company is advancing a therapeutic development pipeline populated with various clinical stage programs built around its two proprietary technologies, known as niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its niclosamide portfolio is led by three clinical programs: FW-COV for COVID-19 gastrointestinal infections; FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis; and FW-ICI-AC for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-associated colitis and diarrhea in advanced oncology patients. Two additional formulations of niclosamide, FW-UC (ulcerative colitis) and FW-CD (Crohn''s disease) are focused to enter into pipeline development. The company is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.